Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 22Sarcoma 2Genitourinary 2CNS 2Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Resectable MMR-deficient Solid Tumors 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × balstilimab × Other solid neoplasm × Clear all
NCT06279130 2026-03-05

NEOASIS

The Netherlands Cancer Institute

Phase 2/3 Recruiting
133 enrolled
Other solid neoplasm

Resectable MMR-deficient Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡